Fulcrum Therapeutics, Inc. (FULC)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

3.77 on 9 Oct 2026

5 buys6 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$74.88M

Free cash flow

$60.38M

Return on equity

-21.5%

Return on capital

-19.2%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
17 Jul 2026	TANG KEVIN 10% owner	Bought	$179.33K	0.7%
16 Jul 2026	TANG KEVIN 10% owner	Bought	$415.35K	1.7%
15 Jul 2026	TANG KEVIN 10% owner	Bought	$382.26K	1.6%
14 Jul 2026	TANG KEVIN 10% owner	Bought	$462.91K	1.9%
13 Jul 2026	TANG KEVIN 10% owner	Bought	$45.90K	0.2%
26 Jun 2026	Ezekowitz Alan Director	Sold at will	$65.61K	62.2%

33out of 100

Profitability 33

Financial strength 59

Growth 0

Insiders 40

Strongest on financial strength (59), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$1.49M

5 buys, 1 buyer

Sold

$58.99M

6 sales

Planned sales

under a 10b5-1 plan